[342 Pages Report] The global oncology blood testing market size is likely to be valued at USD 3,851.7 Million in 2022 and is expected to reach USD 18,278.2 Million by 2032. The market is likely to exhibit immense growth at a CAGR of 15.2% during the forecast period.
| Attributes | Details |
|---|---|
| Oncology Blood Testing Market Size (2022) | USD 3,851.7 million |
| Oncology Blood Testing Market Size (2032) | USD 18,278.2 million |
| Oncology Blood Testing Market CAGR | 15.2% |
To reduce gaps in precision medicine practice, companies provide various molecular decision support systems that amalgamate genomic and clinical data surging the demand for oncology blood testing. Researchers enabled the diagnosis of genetic mutations of distinct cancers owing to the latest research and advancements surging the adoption of oncology blood testing.
The ability to detect cancerous cells through advanced human genome sequencing expands the oncology blood testing market share. The rising number of people getting diagnosed with cancer increases expenditure on research, further propelling the oncology blood testing market size. The oncology blood testing market growth through 2031 owes to the surge in technological innovation and advancements.
The increasing cost of development and sequencing of the Human Genome Project in the field of genomics owing to the proliferation of sequencing techniques such as NGS propels the oncology blood testing market growth.
Multiple investment programs in precision medicine by key companies drive the demand for oncology blood testing. The adoption of oncology blood testing increases with the hike in the availability of advanced molecular techniques for diagnosis.
Growing awareness about advanced treatment therapies amongst the population expands the oncology blood testing market share. Demand for oncology blood testing grows owing to favorable and uncomplicated reimbursement policies. Increasing cases of hematologic or blood cancer grow the demand for oncology blood testing.
Monitoring the status of minimal residual disease due to rising cases of myeloma cancers and lymphoma along with leukemia in patients escalates the adoption of oncology blood testing. Increasing awareness about blood cancer and its early diagnosis disseminated by government and non-government organizations boosts the oncology blood testing market share.
High prevalence and incidence of cancer, inducing a rapid surge in the burden of sample processing in healthcare facilities, bolsters the oncology blood testing market size. Cancer detection in blood via blood testing assays and kits with the capability of being an efficient diagnostic tool increases the adoption of oncology blood testing. The rising demand for preventative care and accurate diagnosis propels the adoption of oncology blood testing.
The number of cancer cases in the world in 2018 was 18.0 Million, according to the World Health Organisation (WHO), which promises growth of the oncology blood testing market share. Various academic and research witnessing an increase in the number of research studies to develop genetic testing for various blood cancers increases demand for oncology blood testing. The oncology blood testing market size broadens owing to a rise in product approvals.
The presence of healthcare professionals to conduct diagnostic tests surged the adoption of oncology blood testing. The availability of specialized laboratory settings expands the oncology blood testing market share. The affordability of instruments used for blood cancer diagnosis assists in the growth of the oncology blood testing market size.
The effectiveness and credibility of new diagnostic methods elevate the demand for oncology blood testing. The rise in PCR-based tests to detect IDH1 genetic mutations in the bone marrow and blood samples extends the oncology blood testing market growth.
Uncertain reimbursement scenarios in undeveloped regions curb the adoption of oncology blood testing. Diagnostic tools to detect cancer using blood samples, being under development and clinical trial stage, thus being unavailable commercially hinders the oncology blood testing market growth.
Lockdown restrictions due to COVID-19 disrupting the supply chain hampered the demand for oncology blood testing. High costs associated with molecular diagnostics and budgetary limitations obstruct the demand for oncology blood testing. The requirement and sporadic availability of sophisticated facilities further impede the oncology blood testing market growth.
Improving the efficiencies and precision in cancer diagnostics and prevention via new innovative technologies like fluid biopsies, real-time cancer diagnostics, digital PCR, immunohistochemistry, next-generation sequencing (NGS), molecular testing, and cytogenetics escalates the adoption of oncology blood testing. Public and private partnerships and movements toward molecular pathology escalate the demand for oncology blood testing.
A growing number of FDA approvals for NGS-based tests in the USA further propels the oncology blood testing market growth. Increasing collaborations between manufacturers in the market grow the demand for oncology blood testing. Rising conferences on personalized medicines bolster the adoption of oncology blood testing.
Advancements in genetic testing generating a significant impact on diagnostic trends increase the demand for oncology blood testing. An increase in the availability of technologically advanced products for the diagnosis of acute myeloid and leukemia progresses the oncology blood testing market share.
An increase in the co-development of the drug-diagnostics model further expands the oncology blood testing market size. A greater understanding of diagnostic procedures and the availability of technologically advanced products for diagnosis grows the demand for oncology blood testing. Growth in the expenditure and implementation of R&D activities further expand the oncology blood testing market size.
North America dominates the oncology blood testing market share with a revenue of 52.6% in 2022.
This is owing to favourable reimbursement policies and increase in cancer cases amongst the population, along with the awareness on early diagnosis of cancer. This region necessitates the demand for oncology blood testing and advanced technologies to prevent, diagnose and treat cancer.
The growth of the market is further attributed to the rising cases of leukaemia, lymphoma, and multiple myeloma. The survival rate for the disease is approximated to be 86.6% due to the timely diagnosis and emergence of novel therapies.
Europe registers the second largest oncology blood testing market share with a revenue of 30.6% in 2022.
Owing to easy regulatory approval for in-vitro cancer diagnostics, the Europe oncology blood testing market promises growth. The interesting incidence of multiple myeloma across Europe, further fuels the oncology blood testing market growth.
The Asia Pacific is expected to grow in the global oncology blood testing market share.
Growth in the prevalence of blood cancer in several countries of this region.
Increasing number of research activities regulated by various academic research academies further propels the global market growth.
How is the Start-up Ecosystem in the Oncology Blood Testing Market?
Changes in the market and the advent of new technologies contributing to the research and development of new diagnostic tools that aid in the treatment and prevention of cancer are gaining significant popularity.
The awareness of early diagnosis and an interesting number of cancer patients throughout the world surges the perpetual research work against the constant emergence of this fatal illness.
Certain start-up companies are contributing to the overall market growth by devising strategies to counteract blood cancer in the population.
Adaptive Biotechnologies, Grail, Abingdon Health, Freenome, Vivia Biotech, Genoptix, Biofluidica, SkylineDX, etc. provide clinical diagnostics, gene expression profiling tests for personalized medicine, liquid biopsy tests using CTCs, and help scientists and clinicians in research and drug development.
Some of the key market participants in the oncology blood testing market are Guardant Health Inc., Trovagene Inc., Genomic Health Inc., Foundation Medicine Inc., Exosome Diagnostics, Pathway Genomics Corporation, F. Hoffman-La Roche Ltd., Abbott Laboratories, EntroGen Inc., Qiagen N.V., Cepheid, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Illumina Inc., CORE Diagnostics, Genoptix Inc., GenPath, NeoGenomics Laboratories Inc., Siemens, MolecularMD, ArcherDx Inc., ARUP Laboratories., Invivoscribe Inc., GenPath, Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., Roche Holding A.G., Invitae Corporation, Asuragen Inc., Molecularmd, EntroGen, Cepheid, Cancer Genetics, Adaptive Biotechnologies, Grail, Abingdon Health, Freenome, Vivia Biotech, Biofluidica, SkylineDX, Biodesix Inc., NovellusDX, BioNTech SE, etc.
They aim to research and develop diagnostic tools that aid in early detection of cancer in patients. Using liquid biopsies to detect the life threatening disease and try and combat it in time, is the utmost goal of healthcare centers – with the assistance of these key players, the healthcare sector is improving in this arena.
Some of the recent developments in the oncology blood testing market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 15.2% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2016 to 2021 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Types, Application, End User, and Region. |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Guardant Health Inc.; Trovagene Inc.; Genomic Health Inc.; Foundation Medicine Inc.; Exosome Diagnostics; Pathway Genomics Corporation; F. Hoffman-La Roche Ltd.; Abbott Laboratories; EntroGen Inc.; Qiagen N.V.; Cepheid; Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc.; Illumina Inc.; CORE Diagnostics; Genoptix Inc.; GenPath; NeoGenomics Laboratories Inc.; Siemens; MolecularMD; ArcherDx Inc.; ARUP Laboratories.; Invivoscribe Inc.; GenPath; Laboratory Corporation of America Holdings; Luminex Corporation; Myriad Genetics Inc.; Roche Holding A.G.; Invitae Corporation; Asuragen Inc.; Molecularmd; EntroGen; Cepheid; Cancer Genetics; Adaptive Biotechnologies; Grail; Abingdon Health; Freenome; Vivia Biotech; Biofluidica; SkylineDX; Biodesix Inc.; NovellusDX; BioNTech SE; etc. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Table 1: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 3: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 4: Global Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 5: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 7: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 8: North America Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 9: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 11: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 12: Latin America Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 13: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 15: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 16: Europe Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 17: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 19: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 20: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 21: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by Test Type, 2017-2032
Table 23: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 24: MEA Oncology Blood Testing Market Value (US$ Mn) Forecast by End User, 2017-2032
Figure 1: Global Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 2: Global Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 3: Global Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 4: Global Oncology Blood Testing Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 9: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 10: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 11: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 12: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 13: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 14: Global Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 15: Global Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 16: Global Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 17: Global Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 18: Global Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 19: Global Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 20: Global Oncology Blood Testing Market Attractiveness by Region, 2022-2032
Figure 21: North America Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 22: North America Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 23: North America Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 24: North America Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 29: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 30: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 31: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 32: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 33: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 34: North America Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 35: North America Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 36: North America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 37: North America Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 38: North America Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 39: North America Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 40: North America Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 42: Latin America Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 43: Latin America Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 44: Latin America Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 49: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 50: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 51: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 52: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 53: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 54: Latin America Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 55: Latin America Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 56: Latin America Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 57: Latin America Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 58: Latin America Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 59: Latin America Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 60: Latin America Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 61: Europe Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 62: Europe Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 63: Europe Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 64: Europe Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 69: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 70: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 71: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 72: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 73: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 74: Europe Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 75: Europe Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 76: Europe Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 77: Europe Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 78: Europe Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 79: Europe Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 80: Europe Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 82: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 83: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 84: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 89: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 90: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 91: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 92: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 93: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 94: Asia Pacific Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 95: Asia Pacific Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 96: Asia Pacific Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 97: Asia Pacific Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 98: Asia Pacific Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 99: Asia Pacific Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 100: Asia Pacific Oncology Blood Testing Market Attractiveness by Country, 2022-2032
Figure 101: MEA Oncology Blood Testing Market Value (US$ Mn) by Test Type, 2022-2032
Figure 102: MEA Oncology Blood Testing Market Value (US$ Mn) by Application, 2022-2032
Figure 103: MEA Oncology Blood Testing Market Value (US$ Mn) by End User, 2022-2032
Figure 104: MEA Oncology Blood Testing Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by Test Type, 2017-2032
Figure 109: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by Test Type, 2022-2032
Figure 110: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Test Type, 2022-2032
Figure 111: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 112: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 113: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 114: MEA Oncology Blood Testing Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 115: MEA Oncology Blood Testing Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 116: MEA Oncology Blood Testing Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 117: MEA Oncology Blood Testing Market Attractiveness by Test Type, 2022-2032
Figure 118: MEA Oncology Blood Testing Market Attractiveness by Application, 2022-2032
Figure 119: MEA Oncology Blood Testing Market Attractiveness by End User, 2022-2032
Figure 120: MEA Oncology Blood Testing Market Attractiveness by Country, 2022-2032
The oncology blood testing market is likely to generate a CAGR of 15.2% during the forecast period.
North America is the leading oncology blood testing market.
By 2032, the oncology blood testing market is likely to grow to a valuation of USD 18,278.2 Million.
Explore Similar Insights
Oncology Blood Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
